Special Issue "Immuno-Active Cancer Therapeutics"
Deadline for manuscript submissions: closed (30 June 2018).
Interests: oncolytic viruses; tumor vaccines; tumor peptides; neoantigens; dendritic cells; checkpoint inhibitors
Special Issues and Collections in MDPI journals
Spearheaded by checkpoint inhibitors, immunotherapy has established its role in the treatment of many types of cancer. With promising advances made with dendritic cell-based tumor vaccines, engineered tumor cell vaccines, peptide vaccines, CAR T cell therapy, bi-specific antibodies, and the first oncolytic virus-based immune-active treatment for melanoma, the field is ready for the crucial discoveries that will propel these and other immuno-active modalities to the forefront of cancer treatment. The challenges include gaining a deeper understanding of tumor-stromal interactions and effective tools to remove the obstacles to immune-based recognition of a wider range of tumors than presently possible. In addition, the metabolism, microbial make-up and neurophysiological status of the patients crucially affects various immune functions, constituting a rapidly expanding area of research that is expected to have a major impact for the efficacy of immunotherapies and in treatment design. Moreover, successful eradication of cancer will most likely necessitate rational combinations of immune modulating interventions, be it using chemicals, nanoparticles, microbes, antibodies or physical stimuli, perhaps on a personalized basis.
We welcome studies that highlight how the immune system can be harnessed to combat cancer and what the obstacles to successful cancer immunotherapy are. We hope to be able to showcase a wide berth of immunologically active cancer treatments and clever combinations thereof.
Dr. Markus Vähä-Koskela
Dr. Vincenzo Cerullo
Dr. Fabrice Le Boeuf
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- oncolytic virus
- checkpoint inhibitor
- cancer vaccine
- tumor microenvironment
- tumor immune evasion